Feldan Therapeutics Accelerates Growth with Strategic Investment from Linearis Ventures

18 Feb 2025

Quebec City, Canada – February 18, 2025 – Feldan Therapeutics ("Feldan"), a clinical-stage pharmaceutical company specialized in the development of treatments based on intracellular delivery of therapeutics, is pleased to announce an investment from Linearis Ventures, supported by Ville de Québec.

View Full Article

Latest

World’s First Wearable Doppler Ultrasound Patch Expands to East Coast to Enhance Patient Safety at The Mount Sinai Hospital

17 June 2025

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

27 May 2025

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

29 April 2025

All Articles

June 17, 2025

World’s First Wearable Doppler Ultrasound Patch Expands to East Coast to Enhance Patient Safety at The Mount Sinai Hospital

June 11, 2025

Genesys Capital is closing its largest fund to date – Genesys Ventures IV LP

May 27, 2025

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

April 29, 2025

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

See All